Login
$TMDX
$91.86 -$0.35 (0.38%) After hours

$TMDX 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent Progress Positions Company for Continued Growth with Several Near- and Mid-Term Catalysts

10 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Andover, Mass. – September 10, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief ...

04 Aug 2026 8-K: Results of Operations and Financial Condition

Andover, Mass. – August 4, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today report...

21 May 2026 8-K: Submission of Matters to a Vote of Security Holders

WHEREAS, the Board and the shareholders of TransMedics Group, Inc. (the “Company”) approved and adopted the TransMedics Group, Inc. 2019 Stock Incentive Plan, as may be amended from time to time (the “Plan”), in 2019; and

05 May 2026 8-K: Results of Operations and Financial Condition

Andover, Mass. – May 5, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported ...

27 Feb 2026 8-K: Results of Operations and Financial Condition

TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results

24 Feb 2026 8-K: Results of Operations and Financial Condition

Andover, Mass. – February 24, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today rep...

04 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

12 Jan 2026 8-K: Entry into a Material Definitive Agreement; Other Events

THIS LEASE (this “Lease”) is entered into as of this 8th day of January, 2026 (the “Execution Date”), by and between BRE-BMR ASSEMBLY INNOVATION I LLC, a Delaware limited liability company (“Landlord”), and TRANSMEDICS GROUP, INC., a Mas...

29 Oct 2025 8-K: Results of Operations and Financial Condition

Andover, Mass. – October 29, 2025 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today repo...

06 Oct 2025 8-K: Completion of Acquisition or Disposition of Assets

As previously disclosed in a Current Report on Form 8-K filed by TransMedics Group, Inc. (the “Company”) on September 5, 2023, a Current Report on Form 8-K filed by the Company on September 12, 2023, a Current Report on Form 8-K filed by...

30 Jul 2025 8-K: Results of Operations and Financial Condition

Andover, Mass. – July 30, 2025 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reporte...

23 May 2025 8-K: Submission of Matters to a Vote of Security Holders

On May 22, 2025, TransMedics Group, Inc. (the “Company”) held its 2025 Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the shareholders of the Company voted on the following proposals:

08 May 2025 8-K: Results of Operations and Financial Condition

Andover, Mass. – May 8, 2025 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported ...

27 Feb 2025 8-K: Results of Operations and Financial Condition

Andover, Mass. – February 27, 2025 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today rep...

21 Feb 2025 8-K: Completion of Acquisition or Disposition of Assets

As previously disclosed in a Current Report on Form 8-K filed by TransMedics Group, Inc. (the “Company”) on September 5, 2023, a Current Report on Form 8-K filed by the Company on September 12, 2023, a Current Report on Form 8-K filed by...

14 Jan 2025 8-K: Completion of Acquisition or Disposition of Assets

As previously disclosed in a Current Report on Form 8-K filed by TransMedics Group, Inc. (the “Company”) on September 5, 2023, a Current Report on Form 8-K filed by the Company on September 12, 2023, a Current Report on Form 8-K filed by...

09 Dec 2024 8-K: Completion of Acquisition or Disposition of Assets

As previously disclosed in a Current Report on Form 8-K filed by TransMedics Group, Inc. (the “Company”) on September 5, 2023, a Current Report on Form 8-K filed by the Company on September 12, 2023, a Current Report on Form 8-K filed by...

02 Dec 2024 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Andover, Mass. – December 2, 2024 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today anno...

28 Oct 2024 8-K: Results of Operations and Financial Condition

Andover, Mass. – October 28, 2024 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today repo...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support